Connect with us

Small Caps

AREV Corporate Update


VANCOUVER, BC – TheNewswire – August 10, 2022 – AREV LIFE SCIENCES GLOBAL CORP. (CSE:AREV) (CNSX:AREV.CN) (OTC: AREVF) ("AREV" or the "Company")…




VANCOUVER, BC – TheNewswire - August 10, 2022 - AREV LIFE SCIENCES GLOBAL CORP. (CSE:AREV) (CNSX:AREV.CN) (OTC: AREVF) ("AREV" or the "Company") AREV Life Sciences Global Corporation announces a corporate update on progress of its business streams.  


Arev, like many other companies, has felt the impact of the lock downs and changes in market conditions as a result of Covid-19, the war in Ukraine and now global inflation. We believe AREV is very well positioned to make a positive impact in the Clinical Nutrition Sector and in the area of Therapeutic Interventions.  


AREV produces ingredients and formulates proprietary therapeutic interventions with plans to deliver innovation in clinical nutrition, proprietary supplements, topicals and rational drug design, based on science. The Company's business model leverages its core competency of extraction to produce unique ingredients and compounds for its pipeline of products. The Company continues in the product development and pre-commercialization stage with an expectation that it will begin commercial sales in 2023.


"We noticed our messaging was not being understood so in an effort to clarify the activities of the company we have created business streams that give us flexibility for the future.", stated Mike Withrow CEO of AREV. He went on to say, "We get a lot done without massive dilution. This move gives us the focus needed for each business stream of the company and makes it easier for the market to understand the synergy between each unit."


The Company has focused its operations as a fully integrated enterprise and is now organized to address three core market segments; 1) Specialty Ingredients with extraction of compounds for consumption and topical use; 2)

Full story available on

Read More

Continue Reading


Are Retail Investors Done? Biggest Liquidation Since 2020 As Retail Is Now ‘Selling The Rally’

Are Retail Investors Done? Biggest Liquidation Since 2020 As Retail Is Now ‘Selling The Rally’

When it comes to the stock purchasing (and…



Are Retail Investors Done? Biggest Liquidation Since 2020 As Retail Is Now 'Selling The Rally'

When it comes to the stock purchasing (and selling) habits of institutional and retail investors, even as the former had aggressively unwound their exposure throughout 2022 with both gross and net leverage at multi-year lows, retail investors showed remarkable stoicism, patience and resiliency. But all that changed in recent weeks, and according to JPMorgan's Peng Cheng, retail traders have now capitulated, not only selling stocks for the second week in a row, but in a stark reversal from their momentum-chasing ways, retail investors sold both the Monday and Tuesday rallies.

  • Specifically, in the past week they net sold - $1.1B (1.9-SD  below 12M average), and more notably they sold the rally on both Monday (SPX +2.59%) and Tuesday (+3.06%). Curiously, they remain buyers in ETFs (+$1.4B) and net bought S&P 500 (+0.7z leverage adjusted) but sold Russell 2000 ETFs (- 2.0z).
  • Retail traders net sold -$2.4B of single stocks. Large cap tech names including AAPL (-$470MM), META (-$134MM), and GOOG (-$128MM), in particular, suffered from heavy selling.

As both retail and gross flows and social media posts show, we are well beyond peak retail enthusiasm and we can now conclude that the distribution phase where institutions sell to retail - which defined markets for much of the past two years - is truly over.

Even more notable is that as the chart below shows, the last two weeks represented the worst selling in single stocks since March 2020 (on the other hand, inflows into ETFs, although showing signs of slowdown, remained positive).

Some more details broken down by industry group and thematic:

  • Large-cap: At the industry group level, volumes were slightly higher, driven by Autos and Consumer Services, partially offset by Tech Hardware. Looking at Large-cap single-stock, retail pared down exposure again this past week (-$2.0B) across most industry groups. We again observed some of the strongest retail selling across Technology, especially Tech Hardware (e.g. AAPL, CSCO). This was partially offset by buying within Autos (e.g. TSLA, RIVN, QS).
  • Thematic: Retail investors again shed exposure this past week across themes, though Green / EV Infrastructure (JPAMIGRN) and Long Rising Oil Beneficiaries (JPAMNRGY) were marginal bright spots. We observed heavier selling across Domestic (JPAMDOME) and Covid-19 Domestic Recovery (JPAMCRDB). On the wage side, we also saw Retail cut exposure to US Wage Growth Sensitive Basket (JPAMWAGG)

Bearish sentiment was also evident in the options market. According to JPM, retail traders sold -$1.0B of delta and bought $520MM of gamma this past week. They supplied -$1.3B of delta on SPX/SPY, QQQ, and IWM, mostly via put option buying.

Finally, just to make things "interesting", here is the latest confirmation that anyone trying to make even a little sense of the market is destined for catastrophic failure: as noted above, JPM said that "retail investors sold the rally on both Monday and Tuesday."

Well, one look at VandaTrack's latest weekly research shows that "retail investors have been chasing the last two days rebound by buying US$ 860 mn worth of US securities on Monday and US$ 960 mn on Tuesday. A considerable amount given that they are usually contrarian and reduce their purchases during rallies. We expect this trend to continue and foresee a slowdown in inflows if the rebound will fade; however, we could see a ramp up in purchases if the rally gains traction."

And while retail investors may have bought... or sold... stock in during the latest meltup, depending on whose "research" one reads, one thing is clear: the recent sell-off in retail favorites such as AAPL and TSLA has had a large impact on retail portfolios’ performance and as of yesterday, the average retail portfolio’s relative drawdown is again close to -32% and has started to underperform the S&P 500 again.

As Vanda notes, "additional losses will be both financially and psychologically hard to handle for the average retail trader", and the greater the eventual drawdown, the less likely retail will be to rush into the next dip and buy it.

Tyler Durden Thu, 10/06/2022 - 15:39

Read More

Continue Reading


What Is the New York Stock Exchange and What Does It Do?

What Is the New York Stock Exchange in Simple Terms?With more than 2 billion shares trading hands each day, the New York Stock Exchange (NYSE) is the world’s…



The New York Stock Exchange is located on Wall Street in New York City.

wdstock from Getty Images Signature; Canva

What Is the New York Stock Exchange in Simple Terms?

With more than 2 billion shares trading hands each day, the New York Stock Exchange (NYSE) is the world’s largest exchange for securities trading, which is the buying and selling of debt or equity, such as stocks and bonds. The NYSE is located in a historic building in the heart of New York City’s financial district at 11 Wall Street.

The NYSE was known for centuries as the "Big Board" because brokers would use an auction-based system to buy or sell shares of stock from its trading floor, and share prices were updated throughout the day on a large board that traders could see from the trading pit. 

A ringing bell signaled the beginning and the end of the trading day. The opening bell signaled the start of the trading day at 9:30 AM, and the closing bell happened at 4:00 PM, marking the end of the trading day. Trades at the NYSE took place on an actual trading floor up until the onset of the COVID-19 pandemic, when everything moved online; floor trading resumed for vaccinated brokers in May 2021.

Is the NYSE a Stock Exchange or a Stock Index?

The NYSE was a privately-owned exchange, or a place for trading, from its inception in the late 1700s until 2006, when it was bought by Intercontinental Exchange, which took shares public. Its ticker symbol is ICE.

However, since the New York Stock Exchange is the world’s largest trading exchange, with over 80% of the S&P 500 companies trading on it, the NYSE Composite, made up of 2,000 stocks listed on the NYSE, has come to be known as a benchmark stock market index. Glancing at how it’s doing gives investors a sense of the overall health of the financial markets. An exchange-traded fund (ETF) based on the NYSE Composite was introduced in 2004; its ticker symbol is NYA.

In addition, the New York Stock Exchange owns a smaller stock exchange, the American Stock Exchange, which it acquired in 2008. Now known as the NYSE American, it is where small-cap companies trade on lower volumes.

What Does the New York Stock Exchange Do? Who Works There? How Does It Make Money?

The NYSE has two purposes:

1. It facilitates buy-and-sell trades of securities.

2. It enables companies to raise capital by selling stock.

The NYSE was originally founded as a space exclusively for securities trading under the Buttonwood agreement in 1792. Prior to that, traders had to sell securities alongside commodities like coffee and tobacco and often had to do so outside, in rain and snow, which is how they got the nickname curbstone brokers.

The Buttonwood Agreement also established regulations and set standard commission fees that brokers could charge clients. Now, with a roof above their heads, traders could call out buy and sell orders from the trading floor; those transactions would be recorded, which provided a level of transparency as well as liquidity that before had not been possible. It was the beginning of efficient market operations as we know them.

Today, computers do most of the buying and selling at the NYSE, although there are still several hundred brokers and traders who shout their orders from the trading pit each day. The scene plays host to dozens of media outlets as well as executives and celebrities who ring the opening bell.

The NYSE makes money through revenues from transaction fees it charges to brokerages, asset-management companies, and market makers. In addition, all members of the NYSE are required to pay yearly membership fees as well as an additional fee to apply.

What Are the New York Stock Exchange’s Hours? Can I visit the NYSE?

The NYSE operates Monday–Friday from 9:30 AM–4:00 PM eastern time. It is closed in observance of the following holidays; when the holiday falls on a Saturday, it closes the Friday before.

  • New Year’s Day
  • Martin Luther King, Jr. Day
  • Washington’s Birthday
  • Good Friday
  • Memorial Day
  • Juneteenth
  • Independence Day
  • Labor Day
  • Thanksgiving Day
  • Christmas Day

The NYSE was open for tours up until the September 11, 2001 attacks; it is no longer accessible to the public.

Which Companies Are Listed in the New York Stock Exchange? How Does a Company Get Listed?

The NYSE lists over 2,000 U.S. and international stocks—for the current lineup, check the directory on its website.

What Is the Difference Between the NYSE and the Nasdaq?

The NYSE and the Nasdaq are both stock exchanges, but the NYSE is much larger. It has a market capitalization of $26 trillion as of 2021, compared with the Nasdaq, which has a market cap of $19 trillion.

In addition, there are several other key differences:

Differences between NYSE and Nasdaq Exchanges

The NYSE sets prices through an auction market, which means that shares are bought directly by buyers from sellers, and share prices are set based on the highest price a bidder is willing to pay and the lowest price a seller will accept.

The Nasdaq uses a dealer market, which means that buyers and sellers do not interact directly; rather, the trades are handled by a dealer, often a larger brokerage known as a market maker, which maintains inventories of stocks and facilitates trades from its own accounts.

Where Is the New York Stock Exchange at Right Now?

For a live feed of NYSE prices, check out its website.

Read More

Continue Reading


Three Stocks Built for Disrupting the Big Pharma Hegemony (TIVC, EMED, ZBH, NVCR, MDT, ZYXI, ECOR, ISRG)

The number one fact in play right now for investors is risk aversion. According to Bank of America strategists, professional money managers are currently…



The number one fact in play right now for investors is risk aversion.

According to Bank of America strategists, professional money managers are currently sitting on their highest cash allocation levels ever. According, large investors are currently sitting on their largest put option holdings ever. And according to the CFTC, hedgers are currently sitting on their largest net short index futures position ever.

If you work in the idea that a major global investment bank (Credit Suisse, NYSE:CS) has seen its credit default swaps skyrocket over the past week (a sign of the market’s belief that a firm could fail) and that a tyrannical madman (Putin) has repeatedly threatened nuclear war over the same period, it’s frankly astonishing the market has been moving higher this week.

But, all of that said, investors are competing for a very limited number of obviously good options right now, with healthcare and technology as structurally advantaged sectors looking ahead at the next cycle.

Right at the heart of that equation, we see a number of interesting stocks with models predicated on disrupting the established status quo in the big pharma space. And it’s no wonder. Given the opioid drug epidemic, pain treatment alternatives have seen enormous growth in recent years, with some very interesting and innovative solutions starting to drive the market.

With that in mind, we take a look below at some of the most compelling stories in the space.

Zimmer Biomet Holdings Inc. (NYSE:ZBH) engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. The company operates through its Americas Orthopedics, EMEA, Asia Pacific, and Americas Spine and Global Dental segments.

The Americas Orthopedics segment consists of the U.S. market and includes other North, Central, and South American markets for the firm’s orthopedic product categories. The EMEA segment focuses on Europe and includes the Middle East and African markets for all product categories except Dental. The Asia Pacific segment consists of Japan, China, and Australia and includes other Asian and Pacific markets for all product categories except Dental. The Americas Spine and Global Dental segment focuses on the U.S. market and includes other North, Central, and South American markets for the firm’s spine business, and all geographic markets for its dental business. This segment is also involved in research, development engineering, medical education, and brand management.

Zimmer Biomet Holdings Inc. (NYSE:ZBH) recently announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Identity Shoulder System for anatomic, reverse and revision shoulder replacement. The Identity Shoulder System is a convertible system that uses proprietary technologies to align each surgeon’s approach to an individual patient’s anatomy, with the goal of alleviating pain and optimizing range of motion. The latest addition to Zimmer Biomet’s portfolio of shoulder replacement systems, the Identity Shoulder System is designed to allow surgeons to devise and execute a patient-specific surgical plan with precision.

“The FDA clearance of the Identity Shoulder System is exciting because it offers surgeons a highly adaptable solution for anatomic, reverse and revision procedures to help patients optimize natural shoulder movement,” said Ivan Tornos, Chief Operating Officer at Zimmer Biomet. “This significant milestone adds to progress in our growing Sports Medicine, Extremities and Trauma (S.E.T.) portfolio, a critical area of focus as we expand our position as a global leader in innovative medical technologies that maximize mobility.”

If you’re long this stock, then you’re liking how the stock has responded to the announcement. ZBH shares have been moving higher over the past week overall, pushing about 5% to the upside on above average trading volume. Shares of the stock have powered higher over the past month, rallying roughly 4% in that time on strong overall action.

Zimmer Biomet Holdings Inc. (NYSE:ZBH) managed to rope in revenues totaling $1.8B in overall sales during the company’s most recently reported quarterly financial data — a figure that represents a rate of top line growth of -12.1%, as compared to year-ago data in comparable terms. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($386.4M against $2.5B, respectively).

Electromedical Technologies Inc. (OTC US:EMED) is flying under the radar as a disruptive force in the pain-free drug-free marketplace. The company’s flagship product, the WellnessPro Plus, uses frequency and electro-modulation to combat pain effectively.

The company’s technology platform has started to ramp up, with management now focused on scaling it worldwide. While EMED is just now starting to scratch the surface of its big-picture sales equation, we are already starting to see strong growth and overall results.

Electromedical Technologies Inc. (OTC US:EMED) just hit the wires this morning with an update that lays out the company’s recent growth and strong prospects.

Electromedical Founder and CEO, Matthew Wolfson, remarked, “Overall we saw around 24% stronger topline performance on a sequential quarterly basis in Q3, with additional orders in the pipeline for Q4. It was our strongest quarter of the year and the second strongest quarter of sales since the pandemic started.”

In terms of key highlights, the company noted that Q3 saw strong overall sales totaling approximately $280,000, beating both Q1 and Q2 2022 sales, it recorded second highest quarterly revenue figure since Q1 2020, closed approximately $900K in financing to expedite development of the new unit, increased distributors and clinics to drive wider market footprint and bolster sales volume, finalized fixed cost investment to secure key components and avoid supply chain bottlenecks, settled negotiations, factory ready for expanded production and negotiated more favorable pricing and terms from suppliers, and participated in exhibiting its flagship product (WellnessPro Plus) at the world’s renowned pain conference in the US (PAINWeek).

The company is riding momentum to close out the year, pointing out that it is continuing to onboard new sales representatives and clinics to expand and expedite Wellness Pro market penetration, its trade shows are paying off in exposure and increased interest, it has achieved new and major product development milestones of Wellness Pro (to be announced in upcoming communication), and its Presale of Wellness Pro units to existing customers of the original legacy unit is expected to start next year in Q2 to expedite cash flow from existing customers.

Electromedical Technologies Inc. (OTC US:EMED) CEO Wolfson noted in conclusion, “Q3 was solid, but we are scaling the business right now, and we know the real meat of the process is still in front of us. The important part is that we have the ability to continue to invest in massively expanding our sales and distribution footprint and maintain our market leading position in proprietary tech and innovation in the drug-free, pain-free marketplace.”

Zynex Inc. (Nasdaq:ZYXI) engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation.

The company also develops a new blood volume monitor for use in hospitals and surgery centers.

Zynex Inc. (Nasdaq:ZYXI) recently announced it has begun enrollments in a large-scale blood loss detection clinical trial with its second-generation monitoring system, the CM-1600. The multi-site trial, first initiated with ClinCept, LLC., in partnership with LifeSouth Community Blood Center, is designed to determine the specificity and sensitivity of the CM-1600 in detecting minor blood loss during a whole blood donation procedure. Zynex Monitoring Solutions expects to continue gaining evidence for the use and application of the CM-1600 throughout the study.

“Clinical trials are vital not only to optimizing the performance of our device but also to building the critical body of evidence clinicians need to gain trust in our patented Relative Index,” said Thomas Sandgaard, CEO, Chairman and Founder.

Even in light of this news, ZYXI hasn’t really done much of anything over the past week, with shares logging no net movement over that period. Shares of the stock have powered higher over the past month, rallying roughly 4% in that time on strong overall action.

Zynex Inc. (Nasdaq:ZYXI) has a significant war chest ($26.9M) of cash on the books, which must be weighed relative to about $18.8M in total current liabilities. ZYXI is pulling in trailing 12-month revenues of $143M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 18.5%.

Other key players in the medical and healthcare disruption business include Tivic Health Systems Inc. (Nasdaq:TIVC), Novocure Ltd. (Nasdaq:NVCR), Medtronic PLC (NYSE:MDT), electroCore Inc. (Nasdaq:ECOR), and Intuitive Surgical Inc. (Nasdaq:ISRG).


For consideration of being featured on WallstreetPR, contact

Please make sure to read and completely understand our disclaimer at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at

The post Three Stocks Built for Disrupting the Big Pharma Hegemony (TIVC, EMED, ZBH, NVCR, MDT, ZYXI, ECOR, ISRG) appeared first on Wall Street PR.

Read More

Continue Reading